{"id":39983,"date":"2013-09-13T17:55:59","date_gmt":"2013-09-13T21:55:59","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=39983"},"modified":"2013-09-13T18:00:55","modified_gmt":"2013-09-13T22:00:55","slug":"all-aboard","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2013\/09\/13\/all-aboard\/","title":{"rendered":"all aboard&#8230;"},"content":{"rendered":"\n<p align=\"center\"><img loading=\"lazy\" decoding=\"async\" width=\"520\" height=\"52\" border=\"1\" src=\"http:\/\/1boringoldman.com\/images\/train.jpg\" \/><\/p>\n<table width=\"95%\" cellspacing=\"0\" cellpadding=\"5\" border=\"0\" align=\"center\">\n<tr>\n<td><span class=\"small\"> <\/p>\n<div align=\"justify\">Dear Friends<\/div>\n<p align=\"justify\">Support for AllTrials around the world is growing and we need to keep it that way as we reach some crucial debates. <\/p>\n<p align=\"justify\">The European Medicines Agency&rsquo;s proposed policy on publishing and sharing information from clinical trials is <a href=\"http:\/\/www.kulahub3.com\/li.aspx?cu=6244823&#038;link=89654\">open for comment<\/a> until 30th  September. Many of you have been involved in getting your organisations  to sign up in support of AllTrials for all trials registered and all  results reported. The EMA&rsquo;s proposals will help to make that happen. But  organisations that want to slow or restrict transparency are already  making their views known. <strong><font color=\"#200020\">Please send comments to the EMA before the  deadline. Even if you can only comment briefly, please do. It is vital  that they hear from the range of bodies and individuals who want an end  to hidden trials. <\/font><\/strong>We will publish our response next week and share it with you in case that helps.<\/p>\n<p align=\"justify\">Last month we published the <a target=\"_blank\" href=\"http:\/\/www.kulahub3.com\/li.aspx?cu=6244823&#038;link=89655\">AllTrials manifesto<\/a>,  which sets out challenges that regulators, companies, researchers,  professional bodies, journals and others are addressing (or should be)  to make sure that all trials are registered and results reported. There  have already been meetings, discussions and documents enlarging on some  of the points in there, such as how registries can work together to  cross reference registered trials and what journals, funders and ethics  committees can do to check up on registration. <\/p>\n<div align=\"justify\">We&rsquo;re  going to link these into the document and map out progress in different  parts of the medical research system. Meantime, here is some of the  news:<\/div>\n<ul>\n<li>\n<div align=\"justify\">In the UK, the Health Research Authority is about to <a target=\"_blank\" href=\"http:\/\/www.kulahub3.com\/li.aspx?cu=6244823&#038;link=89656\">implement its new policy<\/a>  to ensure all UK clinical trials are registered in a publicly  accessible database. From 30th September it will be a breach of good  research practice to fail to register a clinical trial.<\/div>\n<\/li>\n<li>\n<div align=\"justify\"><u><a target=\"_blank\" href=\"http:\/\/www.kulahub3.com\/li.aspx?cu=6244823&#038;link=89657\"><em>PLOS Medicine<\/em> announced<\/a><\/u> that it will now consider retrospectively registered trials for publication.<\/div>\n<\/li>\n<li>\n<div align=\"justify\">The British Pharmacological Society and the American Society for Pharmacology and Experimental Therapeutics have announced their <a target=\"_blank\" href=\"http:\/\/www.kulahub3.com\/li.aspx?cu=6244823&#038;link=89658\">support for the publication of negative findings from early clinical trials<\/a>.<\/div>\n<\/li>\n<li>\n<div align=\"justify\">A new <u><a target=\"_blank\" href=\"http:\/\/www.kulahub3.com\/li.aspx?cu=6244823&#038;link=89659\">paper in the <em>BMJ<\/em><\/a><\/u> shows that only 28% of medical journals require a clinical trial reported in their pages to be registered.<\/div>\n<\/li>\n<li>\n<div align=\"justify\">Trial registries around the world are going to work together to identify practicable ways to complete missing trial information.<\/div>\n<\/li>\n<\/ul>\n<div align=\"justify\">We put campaign news onto our website at <a target=\"_blank\" href=\"http:\/\/www.kulahub3.com\/li.aspx?cu=6244823&#038;link=89660\">www.alltrials.net<\/a>  every day. We are just about to move on making the website, which we  put up in a rush at the start, a more rapid and comprehensive way to  keep up with the campaign developments across the world. If you have  been visiting it and have suggestions please <a target=\"_blank\" href=\"mailto:alltrials@senseaboutscience.org\">email in the next few days.<\/a>       <\/p>\n<p>&nbsp;<\/p>\n<p align=\"justify\">Best wishes<\/p>\n<div>S\u00edle <\/div>\n<\/div>\n<p><\/span><\/td>\n<\/tr>\n<\/table>\n<p>      <\/p>\n<div align=\"justify\">If&nbsp; you signed the AllTrials petition, you probably got the above email. If you haven&#8217;t signed it, there&#8217;s a link right here [upper left] to make it easy. I reproduced the email here to clarify a point. The important action right now is to write the <strong><font color=\"#200020\">European Medicines Agency<\/font><\/strong> [EMA] before September 30th. Here are the operative pieces of information:<\/div>\n<ul>\n<li>\n<div align=\"justify\"><a target=\"_blank\" href=\"http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2013\/06\/news_detail_001825.jsp&#038;mid=WC0b01ac058004d5c1\">The EMA Proposal<\/a>:<br \/>  It gives PHARMA beyond ample protection, but read it if you need proof.     <\/div>\n<\/li>\n<li>\n<div align=\"justify\"><strong><font color=\"#200020\">The reason to write the EMA<\/font><\/strong>:<br \/>  I&#8217;ve tried to outline the attempts by PHARMA to undermine the EMA [<a href=\"http:\/\/1boringoldman.com\/index.php\/2013\/09\/06\/a-deal-breaker\/\">a deal-breaker?&hellip;<\/a>, <a href=\"http:\/\/1boringoldman.com\/index.php\/2013\/09\/12\/an-aside-2\/\">an aside&hellip;<\/a>].     <\/div>\n<\/li>\n<li>\n<div align=\"justify\"><strong><font color=\"#200020\">How to write the EMA<\/font><\/strong>:<br \/>  Their email address is <a href=\"mailto:ctdatapolicy@ema.europa.eu\" target=\"_blank\">ctdatapolicy@ema.europa.eu<\/a>, but they suggest that you use a Submission Form [<a target=\"_blank\" href=\"http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2013\/06\/news_detail_001825.jsp&#038;mid=WC0b01ac058004d5c1#\">here<\/a>]. It&#8217;s a Word File asking for details and I found it ponderous. Torn with indecision, rather than obsess about which to use, I did both. When you look at the Submission Form, you&#8217;ll understand the confusion.     <\/div>\n<\/li>\n<\/ul>\n<div align=\"justify\">And as long as you have pen in hand, quickly sign David Healy&#8217;s petition to AbbVie and Intermune to withdraw their suit against the EMA:    <\/div>\n<ul>\n<li>\n<div align=\"justify\"><strong><font color=\"#200020\">How to sign Dr. Healy&#8217;s petition<\/font><\/strong>:<br \/>It&#8217;s easy. Just <a target=\"_blank\" href=\"http:\/\/www.change.org\/petitions\/richard-gonzalez-of-abbvie-and-daniel-welch-of-intermune-drop-your-legal-action-blocking-access-to-ema-clinical-trial-data?utm_source=guides&#038;utm_medium=email&#038;utm_campaign=petition_lonely\">click here<\/a>&#8230;    <\/div>\n<\/li>\n<\/ul>\n<div align=\"justify\">If you agree that the pharmaceutical industry has abused its place in healthcare beyond endurance, jump on this train headed for <strong><font color=\"#200020\">data transparency<\/font><\/strong>. It&#8217;s the train that&#8217;s finally going to take us where we&#8217;ve been needing to go for a very long time&#8230;<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dear Friends Support for AllTrials around the world is growing and we need to keep it that way as we reach some crucial debates. The European Medicines Agency&rsquo;s proposed policy on publishing and sharing information from clinical trials is open for comment until 30th September. Many of you have been involved in getting your organisations [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-39983","post","type-post","status-publish","format-standard","hentry","category-politics"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/39983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=39983"}],"version-history":[{"count":5,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/39983\/revisions"}],"predecessor-version":[{"id":39988,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/39983\/revisions\/39988"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=39983"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=39983"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=39983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}